Kenvue Inc. Common Stock · Transaction Aug 5, 2026 · Filed Aug 10, 2026 · $1,001 to $15,000
Kenvue Inc
Veridion Score
BETAHIGH CONF · 6/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is KVUE moving today?
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
KVUE overview
Related filings and maps
Congress activity in KVUE
KVUE · Transaction Jun 16, 2026 · Filed Jul 2, 2026 · $1,001 to $15,000
KVUE Common Stock · Transaction Jun 2, 2026 · Filed Jul 6, 2026 · $1,001 to $15,000
KVUE Common Stock · Transaction May 15, 2026 · Filed Jun 9, 2026 · $1,001 to $15,000
Kenvue Inc. Common Stock · Transaction Mar 27, 2026 · Filed Jul 21, 2026 · $1,001 to $15,000
KVUE contract awards, year to date.
Public federal awards linked to this ticker.
KVUE lobbying filings, year to date.
Registered lobbying filings matched to Kenvue Inc.